Search Results

Medivir AB announces that the number of shares and votes in Medivir has changed during June 2024 as a result of the issue of 1,700,000 shares of series C and the reclassification of 114 587 shares of series C to ordinary shares which was carried out as a part of the implementation of the incentive program resolved by the general meeting on 7 May 2024.

Medivir AB announces that the number of shares and votes in Medivir has changed during January 2024 as a result of the rights issue resolved on by Medivir on 7 November 2023 and the directed issue to Hallberg Management AB resolved on by Medivir on 22 January 2024.

Medivir AB announces that the company will participate at Redeye Growth Day, today May 30, 2024.

Medivir AB announced that Medivir’s licensee, Tango Therapeutics, has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts.

Medivir AB announces that the Annual Report for 2023 now is available at the company’s website.

Medivir AB announces that the company will participate at the Investing in Oncology Forum on April 10, 2024.

Medivir AB announced that it has selected a global CRO partner for the planned phase 2b study evaluating fostroxacitabine bralpamide + Lenvima® vs Lenvima alone in second line HCC.

Medivir AB presented positive new data from its ongoing phase Ib / IIa study of fostroxacitabine bralpamide + Lenvima® in advanced hepatocellular carcinoma at the ESMO GI Cancers Congress in Munich, Germany.

Medivir AB announced that an abstract for the combination of fostroxacitabine bralpamide + Lenvima® in hepatocellular carcinoma has been accepted for presentation at the European Society for Medical Oncology Gastrointestinal Cancers Congress in June 26-29, 2024 in Munich.

Medivir AB announces that the company will participate at the Swiss Nordic Bio conference on March 7, 2024.